Subsequent Events |
9 Months Ended |
|---|---|
Jul. 31, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | 17. Subsequent Events The Company has evaluated subsequent events through the date these financial statements were issued. The Company concluded that no subsequent events have occurred that require disclosure except as follows. Subsequent to July 31, 2026, the FDA and the Company reached agreement on the timing of the pre-BLA meeting. Under the terms of certain employee retention agreements, this event results in the related milestone condition being considered probable for accounting purposes. As a result, the Company expects to recognize approximately $0.7 million of expense in the fourth quarter of 2026 related to this milestone. |